Stockscreener 앱 받기
191.09
0.68%
-1.36
전일 마감가:
$192.45
열려 있는:
$191.72
하루 거래량:
605.14K
Relative Volume:
0.08
시가총액:
$337.47B
수익:
$57.37B
순이익/손실:
$4.20B
주가수익비율:
81.31
EPS:
2.35
순현금흐름:
$15.39B
1주 성능:
+1.87%
1개월 성능:
+0.03%
6개월 성능:
+8.88%
1년 성능:
+12.25%
1일 변동 폭
$190.68
$192.66
1주일 범위
$186.67
$197.50
52주 변동 폭
$163.81
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
191.05 | 331.43B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
794.16 | 693.83B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.53 | 373.59B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVS
Novartis Ag Adr
|
120.81 | 241.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
69.10 | 308.01B | 43.59B | 15.04B | 10.74B | 3.3766 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
Sleep App Market Is Booming So Rapidly By 2032 | AbbVie Inc., Johnson & Johnson, Amgen Inc. - openPR.com
A New Playbook for Mid-Cap Biotechs: Glenmark's $700M Oncology Deal with AbbVie Signals Strategic Shifts - AInvest
The Smartest Dividend Stocks to Buy With $300 Right Now - The Motley Fool
A Drop of Innovation: AbbVie's Omega-3 Eye Drops and the Disruption of Dry Eye Care - AInvest
Refresh Releases First of its Kind Eye Drop for Dry Eyes - MarketScreener
AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada - MarketScreener
AbbVie Frees Taxpayers From M&A Capital Loss Limitations - Law360
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal - Reuters
AbbVie and Genmab’s Promising Phase 3 Study for DLBCL: A Potential Game-Changer - The Globe and Mail
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? - Yahoo Finance
AbbVie Beats Investor Class Suit Claiming Humira Kickbacks (2) - Bloomberg Law News
AbbVie & IGI Enter Global Licensing Agreement for Trispecific Antibody - Contract Pharma
Dividend Roundup: CVS Health, Procter & Gamble, AbbVie, Colgate-Palmolive, and more (PG:NYSE) - Seeking Alpha
Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Dividend Investors: Don't Be Too Quick To Buy AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend - simplywall.st
AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody - pharmaphorum
FiDi-based drug company inks $1B oncology deal with AbbVie - Crain's New York Business
Glenmark-AbbVie Deal Lifts Optimism on India’s Biotech Stocks - Bloomberg.com
Glenmark Pharma shares surge after its U.S arm, AbbVie ink pact for investigational cancer drug - The Hindu
India’s Glenmark Pharma shares hit record high on AbbVie cancer drug deal - Investing.com
Glenmark Unit to License Blood Cancer Drug to Abbvie for $700 Million Upfront - Bloomberg.com
Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie - MarketScreener
AbbVie Shares Climb on $700 Million Licensing Deal with IGI Therapeutics - MSN
AbbVie (ABBV) Laps the Stock Market: Here's Why - Yahoo Finance
Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal - BioWorld MedTech
AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025 - insights.citeline.com
Wall Street Stunned: AbbVie Drops $700M on a Little-Known Indian Cancer Drug - Yahoo Finance
AbbVie Enters Licensing Agreement For IGI Therapeutics’ Experimental Oncology Drug: Retail Cheers - Stocktwits
Why Is AbbVie Stock Trading Higher On Thursday? - Benzinga
AbbVie Strikes $2B Licensing Deal with IGI Therapeutics - USA Herald
AbbVie expands oncology pipeline with exclusive licensing agreement - The Business Journals
AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma - MedCity News
Glenmark unit clinches $700mn licensing deal for its cancer drug | Company Business News - Mint
Pfizer and AbbVie Advance Pediatric Antibiotic Study with ATM-AVI - TipRanks
AbbVie Pays Up To $2B For Oncology Licensing Agreement - Law360
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody - Yahoo Finance
AbbVie to pay $700M for trispecific drug from Ichnos Glenmark - BioPharma Dive
AbbVie stock jumps after $700 million licensing deal with IGI Therapeutics - Investing.com
Glenmark arm inks $700 million licensing deal with US-based AbbVie - Business Standard
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B - BioSpace
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact - Reuters
AbbVie and Ichnos Glenmark sign licensing deal for trispecific antibody - Seeking Alpha
AbbVie and Ichnos Glenmark ink antibody license deal - The Pharma Letter
AbbVie bets on 'new frontier' in immuno-oncology with $1.9B trispecific deal - FirstWord Pharma
AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody - MarketScreener
AbbVie Signs Deal With IGI Therapeutics To Develop ISB 2001 For Oncology, Autoimmune Diseases - Nasdaq
AbbVie licenses IGI’s multiple myeloma treatment in $1.9 billion deal - Investing.com
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody - PR Newswire
Tax Court Breaks New Ground on the Deductibility of Termination Fees with AbbVie Ruling - proskauertaxtalks.com
Pharmaceutical giant AbbVie wants to expand its presence in Worcester - Worcester Telegram
Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV) - Insider Monkey
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애브비 주식 (ABBV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER |
Mar 31 '25 |
Sale |
210.08 |
58,832 |
12,359,504 |
53,234 |
0.20%
0.46%
자본화:
|
볼륨(24시간):